Renal physiology

Creatinine Assay Kits Market, Forecast to 2025 - Technological Advancements in Biomedical Research Pertaining to Kidney Disorders is Driving Market Growth

Retrieved on: 
Friday, April 17, 2020
Branches of biology, Renal physiology, Physiology, Medical specialties, Creatinine, Guanidines, Metabolism, Renal function, Kidney diseases, Renal angina

The Global Creatinine Assay Kits Market is expected to register a CAGR of 5.3% during the forecast period.

Key Points: 
  • The Global Creatinine Assay Kits Market is expected to register a CAGR of 5.3% during the forecast period.
  • Increasing incidence of renal disorders and other chronic disorders, technological advancements in biomedical research pertaining to kidney disorders and increasing research and development initiatives are the key driving factors in creatinine assay kits market.
  • Increasing incidence of renal disorders and other chronic disorders impacting renal function, technological advancements in biomedical research pertaining to kidney disorders are the key driving factors in the Jaffe's kinetic test kits segment.
  • North America is expected to hold a major market share in the global creatinine assay kits market due to increasing incidence of renal disorders and other chronic disorders impacting renal function and technological advancements in biomedical research pertaining to kidney disorders in this region.

Global Creatinine Assay Kits Market Insights, 2020-2025 - Jaffe's Kinetic Test Kits Expected to Hold Major Market Share - ResearchAndMarkets.com

Retrieved on: 
Friday, April 17, 2020
Medical Supplies, Health, Branches of biology, Renal physiology, Biology, Chemistry, Creatinine, Guanidines, Metabolism, Jaffe reaction, Renal function, Kidney

The Global Creatinine Assay Kits Market is expected to register a CAGR of 5.3% during the forecast period.

Key Points: 
  • The Global Creatinine Assay Kits Market is expected to register a CAGR of 5.3% during the forecast period.
  • Jaffe reaction is a colorimetric method used in clinical chemistry to measure creatinine levels in blood and urine using Jaffe's Kinetic Test Kits.
  • North America is expected to hold a major market share in the global creatinine assay kits market due to increasing incidence of renal disorders and other chronic disorders impacting renal function and technological advancements in biomedical research pertaining to kidney disorders in this region.
  • The Creatinine Assay Kits Market is highly fragmented competitive and consists of several major players.

CHF Solutions Convene Physicians to Discuss Cardio-Pulmonary-Renal Management of COVID-19 Patients

Retrieved on: 
Wednesday, April 8, 2020
Renal physiology, Ultrafiltration, Hypervolemia, CHF

Our dedication to helping treat patients during this pandemic continues to drive the decision we are making, said John Erb, CEO of CHF Solutions.

Key Points: 
  • Our dedication to helping treat patients during this pandemic continues to drive the decision we are making, said John Erb, CEO of CHF Solutions.
  • We have been hearing from distinguished physicians that our ultrafiltration therapy has aided in the treatment of patients with COVID-19.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.
  • CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 [email protected] MEDIA: Jessica Stebing Health+Commerce 260-336-6202 [email protected]

CHF Solutions Doubles Production Staff of Aquadex SmartFlow™ Consoles Due to Hospital Demand

Retrieved on: 
Thursday, April 2, 2020
Chemistry, Natural sciences, Membrane technology, Physical sciences, Renal physiology, Ultrafiltration, Hypervolemia, CHF

We have hired and trained more production builders at our manufacturing facility in Minnesota to ensure that physicians, nurses and the clinical staff have the solutions they need to treat patients impacted with COVID-19.

Key Points: 
  • We have hired and trained more production builders at our manufacturing facility in Minnesota to ensure that physicians, nurses and the clinical staff have the solutions they need to treat patients impacted with COVID-19.
  • CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system.
  • The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy.
  • CONTACTS INVESTORS: Claudia Napal Drayton Chief Financial Officer, CHF Solutions, Inc. 952-345-4205 [email protected] MEDIA: Brad Perriello Health+Commerce 617-817-1385 [email protected]

Mallinckrodt Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration (FDA) for Terlipressin for the Treatment of Patients with Hepatorenal Syndrome Type 1 (HRS-1)

Retrieved on: 
Tuesday, March 17, 2020
Medical specialties, Organ systems, Branches of biology, Peptides, Neuroendocrinology, Neuropeptides, Orgasm, Renal physiology, Vasopressin, American Association for the Study of Liver Diseases, Liver, Terlipressin

The company previously announced the rolling submission, which it initiated in February.

Key Points: 
  • The company previously announced the rolling submission, which it initiated in February.
  • Initial results were presented at The Liver Meeting2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
  • Terlipressin is a potent vasopressin analogue selective for V1 receptors being investigated for the treatment of HRS-1 in the U.S. andCanada.
  • Mallinckrodtuses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information.

CHF Solutions Receives CE Mark for its New Aquadex SmartFlow™ Console

Retrieved on: 
Wednesday, February 5, 2020
Chemistry, Natural sciences, Membrane technology, Physical sciences, Filtration, Renal physiology, Ultrafiltration, Hypervolemia, CHF

EDEN PRAIRIE, Minn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the receipt of a CE Mark for its Aquadex SmartFlow console, its next generation ultrafiltration system.

Key Points: 
  • EDEN PRAIRIE, Minn., Feb. 05, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS) today announced the receipt of a CE Mark for its Aquadex SmartFlow console, its next generation ultrafiltration system.
  • We are proud of achieving this milestone this early in the first quarter, said John Erb, chairman and CEO of CHF Solutions.
  • The CE Mark for our new Aquadex SmartFlow console allows us to continue the expansion of our business internationally and demonstrates our commitment to changing the lives of patients suffering from fluid overload throughout the world.
  • The company is focused on developing, manufacturing, and commercializing the Aquadex FlexFlow and Aquadex SmartFlow systems for ultrafiltration therapy.

Quantum Genomics to Present at the Gordon Research Conference 2020 Dedicated to the Renin Angiotensin Aldosterone System

Retrieved on: 
Wednesday, January 15, 2020
Branches of biology, Enzymes, Medical specialties, Peptide hormones, Endocrinology, Renal physiology, Renin, Angiotensin, Raas, Glutamyl aminopeptidase

Dr. Solene Boitard-Joanne, Pharmacology Department of Quantum Genomics, will present preclinical results of firibastat in mice after myocardial infarction, obtained in collaboration with the INSERM laboratory directed by Dr. Catherine Llorens-Corts at the Collge de France.

Key Points: 
  • Dr. Solene Boitard-Joanne, Pharmacology Department of Quantum Genomics, will present preclinical results of firibastat in mice after myocardial infarction, obtained in collaboration with the INSERM laboratory directed by Dr. Catherine Llorens-Corts at the Collge de France.
  • Study Title: Brain Renin-Angiotensin System Blockade with Firibastat, an Orally Active, Central Acting Aminopeptidase A Inhibitor Prodrug Prevents Cardiac Dysfunction After Myocardial Infarction in Mice
    The Gordon Research Conference "Angiotensin" is a prestigious scientific congress, bringing together researchers and scientific experts from around the world, where the latest discoveries and advances in the field of the renin angiotensin aldosterone system (RAAS) are presented.
  • Quantum Genomics is also announcing its financial timetable for the year 2020:
    Quantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI).
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.

Alnylam Initiates ILLUMINATE-C Phase 3 Study of Lumasiran for the Treatment of Advanced Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

Retrieved on: 
Saturday, November 9, 2019
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Kidney diseases, Branches of biology, Primary hyperoxaluria, Hydroxyacid oxidase (glycolate oxidase) 1, Hyperoxaluria, Renal physiology, Creatinine, Medical specialties, Medicine

This study complements our comprehensive clinical development plan for lumasiran, led by our ILLUMINATE-A pivotal study with results expected later this year and our ILLUMINATE-B study in young pediatric patients.

Key Points: 
  • This study complements our comprehensive clinical development plan for lumasiran, led by our ILLUMINATE-A pivotal study with results expected later this year and our ILLUMINATE-B study in young pediatric patients.
  • Patients also experienced an 82 percent mean maximal reduction in urinary oxalate:creatinine ratio (range: 62-94 percent) after lumasiran dosing across all cohorts (N=20).
  • The Phase 2 OLE safety results were based on a median study duration of 10.4 months (range: 7-17 months) since the first dose administered in the OLE study.
  • Lumasiran is an investigational, subcutaneously administered RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) in development for the treatment of primary hyperoxaluria type 1 (PH1).

AstraZeneca to Present Pivotal Roxadustat Phase III Data at the American Society of Nephrology Kidney Week 2019

Retrieved on: 
Wednesday, October 30, 2019
Biotechnology, Pharmaceutical, Health, Branches of biology, Medical specialties, Blood tests, Anatomy, Renal physiology, Kidney diseases, Guanidines, Acute kidney injury, Organ failure, Dapagliflozin, Loop diuretic, Renal function

For a complete list of AstraZeneca data presentations during Kidney Week 2019, please access the ASN website .

Key Points: 
  • For a complete list of AstraZeneca data presentations during Kidney Week 2019, please access the ASN website .
  • Assess and correct volume status before initiating FARXIGA in patients with impaired renal function, elderly patients, or patients on loop diuretics.
  • Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level.
  • If acute kidney injury occurs, discontinue and promptly treat
    Increases in serum creatinine and decreases in eGFR may be observed with initiation of FARXIGA.

Abington Hospital Begins a 344 Patient Retrospective Clinical Study to Analyze Experience with CHF Solutions’ Aquadex FlexFlow® System

Retrieved on: 
Thursday, October 24, 2019
Renal physiology, Ultrafiltration

We hope that this retrospective review of 344 patients will highlight the patient selection criteria and ultrafiltration rates associated with safe and effective mechanical decongestion in heart failure patients.

Key Points: 
  • We hope that this retrospective review of 344 patients will highlight the patient selection criteria and ultrafiltration rates associated with safe and effective mechanical decongestion in heart failure patients.
  • Regular analysis of professional experience with our Aquadex FlexFlow system is helpful to healthcare providers to better understand optimal management of fluid overload and use of our system, said John Erb, chairman and CEO of CHF Solutions.
  • Abington Hospital, founded in 1914, is the largest community teaching hospital in Montgomery and Bucks counties in Pennsylvania.
  • The company is focused on developing, manufacturing, and commercializing the Aquadex FlexFlow system for ultrafiltration therapy.